Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 1,741.95
+6.05 (0.35%)
At close: May 5, 2026
Caplin Point Laboratories Market Cap
Caplin Point Laboratories has a market cap or net worth of 139.82 billion as of May 6, 2026. Its market cap has decreased by -1.60% in one year.
Market Cap
139.82B
Enterprise Value
130.85B
Revenue
20.92B
Ranking
n/a
PE Ratio
22.85
Stock Price
1,741.95
Market Cap Chart
Since February 26, 2002, Caplin Point Laboratories's market cap has increased from 5.60M to 139.82B, an increase of 2,497,194.42%. That is a compound annual growth rate of 51.95%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 5, 2026 | 132.41B | -5.39% |
| Dec 31, 2025 | 139.95B | -26.39% |
| Dec 31, 2024 | 190.12B | 84.60% |
| Dec 29, 2023 | 102.99B | 90.47% |
| Dec 30, 2022 | 54.07B | -16.82% |
| Dec 31, 2021 | 65.01B | 69.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 400.18B |
| J. B. Chemicals & Pharmaceuticals | 336.56B |
| AstraZeneca Pharma India | 205.84B |
| Granules India | 176.39B |
| Rubicon Research | 159.07B |
| Jubilant Pharmova | 148.66B |
| CORONA Remedies | 107.69B |
| Viyash Scientific | 87.62B |